Top Institutions in Ophthalmology - Retinal Diseases
Leading academic ophthalmology centers with strong retinal disease research programs and clinical trial expertise in novel therapeutics, including TKIs and anti-VEGF agents, are prioritized. Institutions with robust translational research, large patient populations for retinal diseases, and active participation in multicenter clinical trials inform this ranking.
-
#1
Bascom Palmer Eye Institute, University of Miami
Miami, FL
Bascom Palmer is widely recognized for its pioneering research in retinal diseases and leadership in clinical trials involving novel therapies including TKIs and anti-VEGF agents. Their large patient base and multidisciplinary approach enable significant contributions to improving treatment durability in wAMD and DME.
-
#2
Massachusetts Eye and Ear Infirmary, Harvard Medical School
Boston, MA
Massachusetts Eye and Ear has a robust retinal research program with a focus on innovative drug delivery systems and molecular therapies for retinal diseases. Their integration with Harvard Medical School fosters cutting-edge research and early-phase clinical trials in TKIs and anti-VEGF durability.
-
#3
Wills Eye Hospital, Thomas Jefferson University
Philadelphia, PA
Wills Eye Hospital is renowned for its clinical expertise in retinal diseases and extensive involvement in clinical trials evaluating new therapies for wAMD and DME. Their research includes studies on treatment adherence and real-world outcomes of anti-VEGF and emerging TKI therapies.
-
#4
Johns Hopkins Wilmer Eye Institute
Baltimore, MD
Wilmer Eye Institute combines strong basic science research with clinical trials in retinal diseases, focusing on novel therapeutic targets including TKIs. Their multidisciplinary teams work on improving drug delivery and durability to address unmet needs in wAMD and DME.
-
#5
Duke Eye Center, Duke University
Durham, NC
Duke Eye Center has a strong clinical and research focus on retinal diseases, with active involvement in trials of novel agents including TKIs. Their patient-centered research addresses real-world challenges such as treatment adherence and durability in retinal exudative diseases.